At 10:11 AM 6/11/04, you wrote:
>All Janssen has to do is make an extended release form in the right dose
>for improving lactation, and then submit it as a substantial
>improvement.  Voila, new patent.

Another difference in their submitting anew is that in their early years
they were just recommending it for reflux and it may have not seemed worth
their cost to pursue it further. But a patent and approval in the US now
would net them a $ bundle as it does in other countrie, with the word out
of its lactation benifits.

Patricia Gima, IBCLC
Milwaukee, Wisconsin

Mailto:[log in to unmask]

             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html